Drug Trial Radar · NCT06439563
Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers
Last checked: Nov 19, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
364
Planned (sponsor's estimate)
Start
Oct 22, 2024
Primary completion
Aug 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Onconic Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The sutdy aims to to demonstrate the non-inferiority of JP-1366 10 mg compared to Lanston Capsule 15 mg in preventing NSAIDs-induced peptic ulcers and to compare/evaluate the efficacy and safety of JP-1366 10 mg.
Conditions
- Peptic Ulcer
Interventions
JP-1366 10 mgDrug
JP-1366 10 mg, tablet, orally once a day for up to 24 weeks
Lanston Capsule 15 mgDrug
Lanston Capsule 15 mg orally once a day for up to 24 weeks
JP-1366 10 mg placeboDrug
JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks
Lanston Capsule 15 mg placeboDrug
Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative proportion of subjects who developed peptic ulcersTime frame: at 24 weeks after administration of investigational products
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Konkuk University Medical Center
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.